Skip to Content


Principal Investigator:  Prof. Liam Heaney


Name of the Study: SHAMAL: A Multicentre, Randomised, Open-Label, Parallel-Group, Active-Controlled, Phase IV Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients with Severe Eosinophilic Asthma Treated with Benralizumab

Why is this Study important? This study aims to assess the potential for Fasenra®-treated severe eosinophilic asthma patients to safely and effectively reduce their Symbicort® maintenance asthma treatment burden while maintaining asthma symptom control.

What is the Research question/aim? The rationale for this study is to explore a new precision-based approach to treat severe eosinophilic phenotype asthma patients based on benralizumab (Fasenra®) maintenance treatment plus budesonide/formoterol (Symbicort® 200/6 μg) anti-inflammatory reliever as needed.

Who can take part in the Study?   Patients with severe eosinophilic asthma treated with Benralizumab


Contact Information:

Roisin Stone

Belfast Health and Social Care Trust

51 Lisburn Road

Tel: 02895 041135



NI Clinical Research Facility,
U Floor, Belfast City Hospital,
Lisburn Road, Belfast, BT9 7AB

Tel:+44 (0)28 9504 0342

Connect to the NICRF